(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally...
Stats | |
---|---|
Dagens volum | 290 930 |
Gjennomsnittsvolum | 0 |
Markedsverdi | 0.00 |
EPS | €0.230 ( 2022-06-29 ) |
Last Dividend | €0.163 ( 2022-08-18 ) |
Next Dividend | €0 ( N/A ) |
P/E | 17.31 |
ATR14 | €0 (0.00%) |
GSK plc Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
GSK plc Økonomi
Annual | 2021 |
Omsetning: | €34.11B |
Bruttogevinst: | €22.51B (65.99 %) |
EPS: | €1.102 |
FY | 2021 |
Omsetning: | €34.11B |
Bruttogevinst: | €22.51B (65.99 %) |
EPS: | €1.102 |
FY | 2020 |
Omsetning: | €34.10B |
Bruttogevinst: | €22.40B (65.68 %) |
EPS: | €1.426 |
FY | 2019 |
Omsetning: | €33.75B |
Bruttogevinst: | €21.89B (64.85 %) |
EPS: | €1.158 |
Financial Reports:
No articles found.
GSK plc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.163 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.140 | 2004-02-18 |
Last Dividend | €0.163 | 2022-08-18 |
Next Dividend | €0 | N/A |
Payout Date | 2022-10-06 | |
Next Payout Date | N/A | |
# dividends | 75 | -- |
Total Paid Out | €12.75 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.13 | -- |
Div. Sustainability Score | 8.49 | |
Div.Growth Potential Score | 4.03 | |
Div. Directional Score | 6.26 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
ZEG.DE | Ex Dividend Knight | 2023-08-10 | Semi-Annually | 0 | 0.00% | |
GDX.DE | Ex Dividend Knight | 2023-10-05 | Quarterly | 0 | 0.00% | |
PPX.DE | Ex Dividend Knight | 2023-05-02 | Semi-Annually | 0 | 0.00% | |
BC8.DE | Ex Dividend Knight | 2023-05-26 | Annually | 0 | 0.00% | |
I93.F | Ex Dividend Junior | 2023-08-28 | Quarterly | 0 | 0.00% | |
SMHN.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
COP.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
LAR.DE | Ex Dividend Knight | 2023-09-12 | Quarterly | 0 | 0.00% | |
UNP.DE | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% | |
EBO.DE | Ex Dividend Junior | 2023-05-16 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.149 | 1.500 | 7.01 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0644 | 1.200 | 7.85 | 9.42 | [0 - 0.3] |
returnOnEquityTTM | 0.344 | 1.500 | 7.29 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.785 | -1.000 | 2.15 | -2.15 | [0 - 1] |
currentRatioTTM | 0.789 | 0.800 | -1.055 | -0.844 | [1 - 3] |
quickRatioTTM | 0.183 | 0.800 | -3.63 | -2.90 | [0.8 - 2.5] |
cashRatioTTM | 0.181 | 1.500 | -0.108 | -0.162 | [0.2 - 2] |
debtRatioTTM | 0.306 | -1.500 | 4.91 | -7.36 | [0 - 0.6] |
interestCoverageTTM | 7.03 | 1.000 | 8.51 | 8.51 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.998 | 2.00 | 9.33 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.261 | 2.00 | 9.37 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.606 | -1.500 | 3.58 | -5.37 | [0 - 2.5] |
grossProfitMarginTTM | 0.660 | 1.000 | 2.34 | 2.34 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.162 | 1.000 | 8.77 | 8.77 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.329 | 1.000 | 9.28 | 9.28 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.458 | -0.367 | [0.5 - 2] |
Total Score | 8.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.77 | 1.000 | 8.71 | 0 | [1 - 100] |
returnOnEquityTTM | 0.344 | 2.50 | 8.26 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.261 | 2.00 | 9.58 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.998 | 2.00 | 9.33 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.785 | 1.500 | 2.15 | -2.15 | [0 - 1] |
pegRatioTTM | -0.326 | 1.500 | -5.51 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.233 | 1.000 | 6.67 | 0 | [0.1 - 0.5] |
Total Score | 4.03 |
GSK plc
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.